Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AML multi-gene panel testing: A review and comparison of two gene panels.

Pathology, research and practice - 1 May 2016

Thakral G, Vierkoetter K, Namiki S, Lawicki S, Fernandez X, Ige K, Kawahara W, Lum C

Abstract excerpt

BACKGROUND/OBJECTIVE: Risk adapted therapy is standard practice in Acute Myeloid Leukemia (AML). A common diagnostic approach involves focusing on a three gene panel (CEPBA, FLT3, and NPM1). However, a complete representation of prognostic and predictive factors in AML necessitates an expanded series of genes, due to the dynamic interactions present between concurrent mutations. Hence, the current study aims to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Gene Expression Regulation
Share to NPM1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to TP53 gene

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia, Myeloid, Acute

Share to Nucleophosmin

Share to Prognosis

Source

Identifiers

PMID: 26992835
DOI: 10.1016/j.prp.2016.02.004

Genes

NPM1
FLT3
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AML multi-gene panel testing: A review and comparison of two gene panels.PMID 26992835Read ↗

Identifying prognostic gene panels in acute myeloid leukemia.Semantic proximity Read ↗

DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.Semantic proximity Read ↗

Translational implications of somatic genomics in acute myeloid leukaemia.Semantic proximity Read ↗

Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significanceSemantic proximity Read ↗

Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.Semantic proximity Read ↗

Mutated gene markers predict outcome for patients with AML.Semantic proximity Read ↗

Cooperating gene mutations in acute myeloid leukemia: a review of the literature.Semantic proximity Read ↗

The impact of mutational profiling on AML prognosis.Semantic proximity Read ↗

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.Semantic proximity Read ↗

Genetic profiling in acute myeloid leukaemia--where are we and what is its role in patient management.Semantic proximity Read ↗

Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.Semantic proximity Read ↗

Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.